Gout is a metabolic disorder characterized by elevated uric acid levels in the body, associated with painful arthritis, tophi and nephropathy. The most frequently used pharmacologic urate lowering strategies involve reducing urate production with a xanthine oxidase inhibitor and enhancing urinary excretion of uric acid with a uricosuric agent. Urate lowering agents are limited in number, availability and effectiveness. The emergence of a new medication, febuxostat, to lower serum urate levels is welcome as no new drug have been approved since the introduction of allopurinol, in 1964, and the drugs that are available have limitations owing to inefficacy or toxicity. Febuxostat is a novel, nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout.

译文

痛风是一种代谢性疾病,其特征是体内尿酸水平升高,并伴有疼痛性关节炎,痛风石和肾病。最常用的降低尿酸盐的药物策略包括用黄嘌呤氧化酶抑制剂减少尿酸盐的产生,并用尿酸尿剂增强尿酸的尿排泄。尿酸盐降低剂的数量,可用性和有效性有限。新的药物非布索坦 (febuxostat) 的出现可降低血清尿酸水平,这是值得欢迎的,因为自从别嘌醇 (1964年) 的引入以来,尚未批准任何新药,并且可用的药物由于无效或毒性而受到限制。非布索坦是一种新型的非嘌呤选择性黄嘌呤氧化酶抑制剂,是高尿酸血症和痛风患者别嘌醇的潜在替代品。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录